Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer

Xuemei Yang, Alexa B. Turke, Jie Qi, Youngchul Song, Brent N. Rexer, Todd W. Miller, Pasi A. Jänne, Carlos L. Arteaga, Lewis C. Cantley, Jeffrey A. Engelman, John M. Asara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream acting receptor tyrosine kinases (TK). At present, there is no systematic method to determine which TK signaling cascades activate PI3K in certain cancers, despite the likely utility of such information to help guide selection of tyrosine kinase inhibitor (TKI) drug strategies for personalized therapy. Here, we present a quantitative liquid chromatography tandem mass spectrometry approach that identifies upstream activators of PI3K both in vitro and in vivo. Using non-small cell lung carcinoma to illustrate this approach, we show a correct identification of the mechanism of PI3K activation in several models, thereby identifying the most appropriate TKI to downregulate PI3K signaling. This approach also determined the molecular mechanisms and adaptors required for PI3K activation following inhibition of the mTOR kinase TORC1. We further validated the approach in breast cancer cells with mutational activation of PIK3CA, where tandem mass spectrometry detected and quantitatively measured the abundance of a helical domain mutant (E545K) of PIK3CA connected to PI3K activation. Overall, our findings establish a mass spectrometric approach to identify functional interactions that govern PI3K regulation in cancer cells. Using this technique to define the pathways that activate PI3K signaling in a given tumor could help inform clinical decision making by helping guide personalized therapeutic strategies for different patients.

Original languageEnglish (US)
Pages (from-to)5965-5975
Number of pages11
JournalCancer Research
Volume71
Issue number18
DOIs
StatePublished - Sep 15 2011

Fingerprint

Tandem Mass Spectrometry
Phosphotransferases
Neoplasms
Protein-Tyrosine Kinases
IA 3
Mutation
Receptor Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Liquid Chromatography
Down-Regulation
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yang, X., Turke, A. B., Qi, J., Song, Y., Rexer, B. N., Miller, T. W., ... Asara, J. M. (2011). Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Research, 71(18), 5965-5975. https://doi.org/10.1158/0008-5472.CAN-11-0445

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. / Yang, Xuemei; Turke, Alexa B.; Qi, Jie; Song, Youngchul; Rexer, Brent N.; Miller, Todd W.; Jänne, Pasi A.; Arteaga, Carlos L.; Cantley, Lewis C.; Engelman, Jeffrey A.; Asara, John M.

In: Cancer Research, Vol. 71, No. 18, 15.09.2011, p. 5965-5975.

Research output: Contribution to journalArticle

Yang, X, Turke, AB, Qi, J, Song, Y, Rexer, BN, Miller, TW, Jänne, PA, Arteaga, CL, Cantley, LC, Engelman, JA & Asara, JM 2011, 'Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer', Cancer Research, vol. 71, no. 18, pp. 5965-5975. https://doi.org/10.1158/0008-5472.CAN-11-0445
Yang, Xuemei ; Turke, Alexa B. ; Qi, Jie ; Song, Youngchul ; Rexer, Brent N. ; Miller, Todd W. ; Jänne, Pasi A. ; Arteaga, Carlos L. ; Cantley, Lewis C. ; Engelman, Jeffrey A. ; Asara, John M. / Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. In: Cancer Research. 2011 ; Vol. 71, No. 18. pp. 5965-5975.
@article{0bdae4cfe52342199d3b597b7089e06c,
title = "Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer",
abstract = "Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream acting receptor tyrosine kinases (TK). At present, there is no systematic method to determine which TK signaling cascades activate PI3K in certain cancers, despite the likely utility of such information to help guide selection of tyrosine kinase inhibitor (TKI) drug strategies for personalized therapy. Here, we present a quantitative liquid chromatography tandem mass spectrometry approach that identifies upstream activators of PI3K both in vitro and in vivo. Using non-small cell lung carcinoma to illustrate this approach, we show a correct identification of the mechanism of PI3K activation in several models, thereby identifying the most appropriate TKI to downregulate PI3K signaling. This approach also determined the molecular mechanisms and adaptors required for PI3K activation following inhibition of the mTOR kinase TORC1. We further validated the approach in breast cancer cells with mutational activation of PIK3CA, where tandem mass spectrometry detected and quantitatively measured the abundance of a helical domain mutant (E545K) of PIK3CA connected to PI3K activation. Overall, our findings establish a mass spectrometric approach to identify functional interactions that govern PI3K regulation in cancer cells. Using this technique to define the pathways that activate PI3K signaling in a given tumor could help inform clinical decision making by helping guide personalized therapeutic strategies for different patients.",
author = "Xuemei Yang and Turke, {Alexa B.} and Jie Qi and Youngchul Song and Rexer, {Brent N.} and Miller, {Todd W.} and J{\"a}nne, {Pasi A.} and Arteaga, {Carlos L.} and Cantley, {Lewis C.} and Engelman, {Jeffrey A.} and Asara, {John M.}",
year = "2011",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-11-0445",
language = "English (US)",
volume = "71",
pages = "5965--5975",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer

AU - Yang, Xuemei

AU - Turke, Alexa B.

AU - Qi, Jie

AU - Song, Youngchul

AU - Rexer, Brent N.

AU - Miller, Todd W.

AU - Jänne, Pasi A.

AU - Arteaga, Carlos L.

AU - Cantley, Lewis C.

AU - Engelman, Jeffrey A.

AU - Asara, John M.

PY - 2011/9/15

Y1 - 2011/9/15

N2 - Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream acting receptor tyrosine kinases (TK). At present, there is no systematic method to determine which TK signaling cascades activate PI3K in certain cancers, despite the likely utility of such information to help guide selection of tyrosine kinase inhibitor (TKI) drug strategies for personalized therapy. Here, we present a quantitative liquid chromatography tandem mass spectrometry approach that identifies upstream activators of PI3K both in vitro and in vivo. Using non-small cell lung carcinoma to illustrate this approach, we show a correct identification of the mechanism of PI3K activation in several models, thereby identifying the most appropriate TKI to downregulate PI3K signaling. This approach also determined the molecular mechanisms and adaptors required for PI3K activation following inhibition of the mTOR kinase TORC1. We further validated the approach in breast cancer cells with mutational activation of PIK3CA, where tandem mass spectrometry detected and quantitatively measured the abundance of a helical domain mutant (E545K) of PIK3CA connected to PI3K activation. Overall, our findings establish a mass spectrometric approach to identify functional interactions that govern PI3K regulation in cancer cells. Using this technique to define the pathways that activate PI3K signaling in a given tumor could help inform clinical decision making by helping guide personalized therapeutic strategies for different patients.

AB - Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream acting receptor tyrosine kinases (TK). At present, there is no systematic method to determine which TK signaling cascades activate PI3K in certain cancers, despite the likely utility of such information to help guide selection of tyrosine kinase inhibitor (TKI) drug strategies for personalized therapy. Here, we present a quantitative liquid chromatography tandem mass spectrometry approach that identifies upstream activators of PI3K both in vitro and in vivo. Using non-small cell lung carcinoma to illustrate this approach, we show a correct identification of the mechanism of PI3K activation in several models, thereby identifying the most appropriate TKI to downregulate PI3K signaling. This approach also determined the molecular mechanisms and adaptors required for PI3K activation following inhibition of the mTOR kinase TORC1. We further validated the approach in breast cancer cells with mutational activation of PIK3CA, where tandem mass spectrometry detected and quantitatively measured the abundance of a helical domain mutant (E545K) of PIK3CA connected to PI3K activation. Overall, our findings establish a mass spectrometric approach to identify functional interactions that govern PI3K regulation in cancer cells. Using this technique to define the pathways that activate PI3K signaling in a given tumor could help inform clinical decision making by helping guide personalized therapeutic strategies for different patients.

UR - http://www.scopus.com/inward/record.url?scp=80052815712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052815712&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-0445

DO - 10.1158/0008-5472.CAN-11-0445

M3 - Article

VL - 71

SP - 5965

EP - 5975

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -